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Malnutrition  is common  in alcoholic  liver  disease  and  is  associated  with  high  rates  of  complications
and  mortality.  In  this  article,  the  current  literature  was  reviewed  to highlight  the  relevance  of  proper
nutritional  management  providing  levels  of evidence,  when  available.  A  PubMed  search  was performed
for  English-language  publications  from  1980  through  2014  with  the  keywords:  alcoholic  liver  disease,
nutritional  deﬁciencies,  nutritional  support,  enteral  nutrition,  parenteral  nutrition,  and  protein–energy
malnutrition.  Manuscripts  focused  on  nutritional  approach  in  patients  with  alcoholic  liver  disease  were
selected.
Although  nutritional  support  for  malnourished  patients  improves  the  outcome  of  hospitalization,
surgery,  transplantation  and  reduces  the  complications  of  liver  disease  and  the  length  of  hospital  stay,
speciﬁc  guidelines  are  scanty.  Both  enteral  and  parenteral  nutrition  appear  to improve  nutritional  param-
eters and  liver  function;  however  data  on  survival  is often  conﬂicting.  As micronutrient  depletion  is
common  in  alcoholic  liver  disease  and  each  deﬁciency  produces  speciﬁc  sequelae,  all  cirrhotic  patients
should  be screened  at baseline  for deﬁciencies  of  micronutrient  and  supplemented  as  needed.
In summary,  protein–energy  malnutrition  and  micronutrient  depletion  are  clinical  concerns  in alco-
holic  liver disease.  Nutritional  therapy,  including  enteral  nutrition,  parenteral  nutrition  and  micronutrient
supplementation  should  be  part  of the  multidisciplinary  management  of  these  patients.
©  2015  Editrice  Gastroenterologica  Italiana  S.r.l.  Published  by Elsevier  Ltd.  All  rights  reserved.. Introduction
Alcoholic liver disease (ALD) is the most prevalent cause of
dvanced liver disease in Western countries and represents a neg-
tively relevant co-factor in the progression of chronic liver injury
f different aetiology [1,2].
The term “ALD” includes a wide range of liver injury, including
teatosis with or without ﬁbrosis, alcoholic hepatitis (AH), cirrho-
is and hepatocellular carcinoma, and represents one of the most
ommon indications for liver transplantation (LT) in Europe and the
nited States [3].
Complete alcohol withdrawal represents the key treatment forLD although possibly insufﬁcient when facing with cirrhosis or
evere AH [4]. Several medical approaches have been studied, but
vidence about their effect on survival is still lacking [5].
∗ Corresponding author at: Gastroenterology and Endoscopy Unit, Fondazione
RCCS Ca’ Granda-Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milano,
taly. Tel.: +39 02 55033445; fax: +39 02 55033644.
E-mail address: robertaelisa.rossi@gmail.com (R.E. Rossi).
ttp://dx.doi.org/10.1016/j.dld.2015.05.021
590-8658/© 2015 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. AllMuscle wasting, weight loss, and nutritional deﬁciencies com-
monly occur in ALD, the underlying mechanisms including poor
dietary intake (due to anorexia, altered sense of taste and smell, and
nausea and vomiting), maldigestion and malabsorption (related
to concomitant pancreatic insufﬁciency and bile acid deﬁciency,
respectively), bacterial overgrowth due to reduced motility, loss of
proteins secondary to portal hypertension, hypermetabolic state,
insulin resistance, and impaired protein synthesis due to cytokine-
induced inﬂammatory responses [6–8]. As malnutrition correlates
with both higher rates of complications (variceal bleeding, ascites,
encephalopathy, infections, and hepato-renal syndrome) and mor-
tality, its ﬁnding in ALD may  identify those patients at higher risk
of hepatic decompensation and/or liver-related death [8], as clearly
demonstrated by a recent study on 363 AH patients, reporting a one
year mortality of 14% and 76% in those with mild or severe malnu-
trition, respectively [4]. Furthermore, malnutrition has also been
associated with a longer stay in intensive care units, longer length
of hospital stay, and higher mortality after LT [8].
Although no difference in the prevalence and severity of mal-
nutrition has been observed between ALD and viral-related liver
disease in one series [9]. Caly et al. reported a poorer nutritional
 rights reserved.
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Table 1
Grades of clinical recommendations based on literature studies strength.
Grade of
recommendation
Evidence derived from
A Meta-analysis of randomized controlled trials
B  At least one randomized controlled trial, one
controlled study without randomization or one other
type of quasi-experimental study
C Comparative, correlation studies, or case-control
studies
D  Expert committee reports or opinions or clinical
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Table 2
Features of the subjective global assessment [8].
History
Weight change
Dietary intake change (relative to normal)
Gastrointestinal symptoms (that persisted for >2 weeks), including nausea,
vomiting, diarrhoea, anorexia.
Functional capacity: full capacity, dysfunction (working suboptimally,
ambulatory, bedridden).
Disease and its relation to nutritional requirements
Primary diagnosis (specify)
Metabolic demand (stress)
Physical (0 = normal, 1+ = mild, 2+ = moderate, 3+ = severe)
Loss of subcutaneous fat (triceps, chest)
Muscle wasting (quadriceps, deltoids)
Ankle oedema
Sacral oedema
Ascites
SGA rating
A: Well nourished
B: Moderately (or suspected of being) malnourished
to develop malnutrition due to the altered regulation by the
affected liver of both the nutritional status and the energy balance.
Moreover, the presence of CLD may  also decrease the appetite,
thus negatively inﬂuencing nutrient intake. As no difference
Table 3
Parameters aimed at assessing the presence and degree of malnutrition.
Parameters Degree of malnutrition
Mild Moderate Severe
Albumin (g/dL) 3.5–3.0 2.9–2.5 <2.5experience of respected authorities, or both
tatus in patients with alcoholic cirrhosis compared to those with
epatitis C-related cirrhosis [10].
Nutrition plays an important role as supportive therapy, and the
merican Association for the Study of Liver Disease guidelines rec-
mmend that all ALD patients be screened for both protein–calorie
eﬁciency and any speciﬁc micronutrient deﬁciencies (i.e. vitamin
nd mineral deﬁciency) [4].
Based on the above ﬁndings, the present review is aimed at
ddressing both the main patterns of malnutrition in ALD and the
ole of nutritional support in this speciﬁc setting, reporting the
linical recommendations with pertinent evidence-based strength
Centre for Evidence Based Medicine. Levels of Evidence. http://
ww.cebm.net/index.aspx?o¼1025, Table 1).
. Methods
An extensive bibliographical search was performed in PubMed
sing the following keywords: alcoholic liver disease, nutritional
eﬁciencies, nutritional support, enteral nutrition, parenteral
utrition and protein–energy malnutrition, in order to identify
ll the pertinent articles published between 1980 and 2014. The
eference lists from the selected studies were manually exam-
ned to identify further relevant reports. Non-English language
apers were excluded. The quality and strength levels of the results
ere considered and when available meta-analyses and system-
tic reviews, large epidemiological studies and randomized control
rials represented the main source of data.
. Results
A total of 82 articles with the strongest level of evidence speciﬁc
o the scope of this review were identiﬁed.
.1. Nutritional assessment
Nutritional assessment in ALD is based on detailed history and
hysical examination [8]. Of the several clinical markers of malnu-
rition of which none exclusive, the body mass index (BMI, kg/m2)
nd the degree of weight loss are the most relevant ones, in spite
f their potential unreliability in presence of ﬂuid retention [8].
 more comprehensive assessment includes anthropometry and
coring systems such as the Nutrition Risk Screening, which con-
iders the amount and duration of weight loss; the BMI  for adults;
ercentile charts for children; the degree of appetite and the ability
o eat and retain food (i.e. food intake) and ‘stress factors’, i.e. the
ffects of health status on nutritional requirements [8]. A further
idely used tool, whose details are given in Table 2, is the Subjective
lobal Assessment (SGA), based on a standardized questionnaire
imed at assessing any changes in dietary intake, recent changes in
ody weight, gastrointestinal symptoms, functional capacity, and
hysical signs of malnutrition represented by loss of subcutaneous
at or muscle mass, oedema, ascites [8]. In addition, as listed inC:  Severely malnourished
SGA, subjective global assessment.
Table 3, several biochemical markers can help to better deﬁne mal-
nutrition, even though albumin, prealbumin, and transferrin may
lack accuracy as they are synthesized by the liver; a further criti-
cal point is the lack of correlation between these proteins and both
the BMI  and the lean body mass [8]. Moreover, the widespread use
of albumin supplementation in cirrhotic patients can mask actual
plasma albumin levels. The total lymphocyte count (TLC) has also
been proposed as a useful indicator of nutritional status and out-
come, even if its use in patients with hepatic disorders needs further
evaluation as few pertinent studies are currently available [11]. Low
insulin-like growth factor 1 levels may  also be a marker of malnutri-
tion [8], whilst serum creatinine may  not accurately reﬂect the loss
of muscle mass in patients with concomitant renal insufﬁciency.
Noteworthy, in patients with chronic illnesses, including cirrhosis,
muscle wasting can be assessed by measuring psoas muscle thick-
ness by computed tomography (CT) scanning, a novel accurate,
objective marker of nutritional status [8].
Summary: As per current guidelines, the European Society
for Clinical Nutrition and Metabolism (ESPEN) recommends the
bedside nutritional assessment using SGA and anthropometric
measurements [12].
Grade of recommendation: C.
3.2. Protein–energy malnutrition
Malnutrition, characterized by an altered functional and struc-
tural development of an organism, results in an imbalance between
the need, intake and utilization of nutrients and is usually associ-
ated with poor clinical outcomes.
Patients with chronic liver disease (CLD) are particularly proneTransferrin (mg/dL) 200–150 149–100 <100
Pre-albumin (mg/dL) 22–28 17–10 <10
Retinol binding protein (mg/dL) 2.9–2.5 2.4–2.1 <2.1
Lymphocytes/mm3 1500–1200 1199–800 <800
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n malnutrition has been reported between alcoholic and non-
lcohol-related liver diseases [9], the severity of liver damage per
e is crucial in promoting nutritional disorders [6].
The prevalence of protein–calorie malnutrition in patients with
LD ranges from 20% to 60% in outpatients with alcoholic cirrho-
is to the almost 100% in hospitalized patients with AH [6,13,14].
LD represents a strong predictor of malnutrition due to the sev-
ral risk factors associated with chronic alcohol abuse [11] and
rotein–calorie malnutrition may  in turn promote complications,
.g. encephalopathy and/or bacterial infections in ALD patients [15].
oreover, malnutrition may  itself have a negative impact on liver
ntegrity as reported several decades ago in malnourished children
ith kwashiorkor [16]. The current lack of strong clinical practice
uidelines aimed at assessing and grading ALD-related malnutri-
ion accounts for the poor recognition, diagnosis and treatment of
his condition. Accordingly, physicians should be trained to this
peciﬁc ﬁeld as nutritional supplementation can be effective in
mproving liver function and is also positively affecting survival
s suggested by short-term follow-up studies [17–19]. Conversely,
 recent Cochrane meta-analysis failed to conﬁrm a clear-cut ben-
ﬁt on morbidity or mortality from the oral, enteral or parenteral
utritional support even when speciﬁc nutrient deﬁciencies have
een identiﬁed and corrected [7].
Summary:  Although several studies have recommended nutri-
ional supplementation for ALD malnourished patients, the
vailable results are often inconclusive and further studies are
eeded to clearly deﬁne the role of nutritional support.
Grade of recommendation: C.
.3. Micronutrient depletion
The depletion of fat-soluble and water-soluble vitamins or var-
ous minerals is common in patients with ALD, each deﬁciency
roducing speciﬁc symptoms, signs, and complications [6,20]. The
SPEN suggests a baseline screening of all cirrhotics for possible
eﬁciency of serum zinc, calcium and vitamins leading to their
upplementation whenever needed [21] and an annual check-up
nce stable levels are achieved.
The mechanisms underlying micronutrient deﬁciency include
ietary restrictions, frequent paracentesis, diuretic regimens and
actulose therapy. Advanced liver disease associated with cholesta-
is, bacterial overgrowth and/or malabsorption, causes severe
eﬁciencies of fat-soluble vitamins and other nutrients [22].
Summary: Baseline screening for micronutrient depletion and
n appropriate correction when necessary are recommended.
Grade of recommendation: D.
.3.1. Folate deﬁciency
Folate deﬁciency typically characterizes ALD due to reduced
ietary folate intake, intestinal malabsorption, reduced liver uptake
nd storage, and increased urinary excretion [23]. Herbert et al.
riginally reported that 80% of the 70 chronic alcoholics admitted
o a large US urban hospital showed low serum folate levels, with
evere deﬁciency in 44% of them [24].
Both dietary and endogenous folate are involved in the hepatic
ethionine metabolism, which regulates homocysteine levels,
ntioxidant defences, DNA assembly, lipid export, and all epigenetic
ethylation reactions contributing to the gene expression regu-
ation [23]. Dietary folates are metabolized in the liver and other
issues and the ﬁnal metabolite is S-adenosylmethionine (SAM),
hich acts as a methyl donor for all the methylation reactions
nvolving DNA, histones, and proteins [23].
The methionine metabolic pathways are deeply inﬂuenced by
lcohol consumption and folate deﬁciency may  promote liver
isease resulting in defective DNA synthesis and stability, both
ssociated with an increased risk for hepatocellular carcinoma Disease 47 (2015) 819–825 821
[25] and reduced methylation capacity on the expression of genes
related to liver injury [26].
The beneﬁcial effect of both methyl donor SAM and betaine as
protective against the development of experimental ALD in animal
models has been clearly shown [27,28], whilst inconclusive results
have been achieved in the clinical trials focused on the efﬁcacy of
SAM in established ALD [29–31].
Summary: Even though folate should be properly supple-
mented in ALD patients, inconclusive results are available regarding
the therapeutic effect of its ﬁnal metabolite (SAM).
Grade of recommendation: C.
3.3.2. Water-soluble vitamin deﬁciency
Due to the hepatic activation and transport of vitamins B1, B6
and others, water-soluble vitamin deﬁciency commonly occurs in
liver disease.
Thiamine (vitamin B1) deﬁciency is a well-recognized complica-
tion of ALD leading to Wernicke’s encephalopathy and Korsakoff’s
syndrome [20].
As cyanocobalamin (B12) deﬁciency has been reported in CLD,
serum cobalamin levels determination has been suggested; how-
ever, falsely elevated B12 levels have been reported in ALD due
to the inclusion of endogenous metabolically inactive forms of
cobalamin. Accordingly, holotranscobalamin, i.e. the active form of
cobalamin, has been reported to be more reliable as an early marker
of vitamin B12 deﬁcit in alcoholics [32].
Summary: Vitamin B1 and/or B12 deﬁciency should be
promptly treated to avoid complications (i.e. Wernicke’s
encephalopathy, Korsakoff’s syndrome, megaloblastic anaemia,
neuropathies).
Grade of recommendation: C.
3.3.3. Fat-soluble vitamin deﬁciency
Decreased bile acid production, decreased oral intake, derange-
ment in hepatic synthesis of carrier proteins, and other mechanisms
can all account for the deﬁciency of fat-soluble vitamins (i.e., A, D,
E, and K) in CLD patients [20].
Vitamin A deﬁcit with loss of night vision, nyctalopia and more
rarely xerophtalmia, has been reported in alcoholics [33]. Alco-
hol intake has a profound impact on the whole body’s retinoid
homeostasis, but the effects of chronic alcohol consumption are
tissue speciﬁc; in other words, alcohol consumption is associated
with a decrease in the hepatic retinoid content, while extra-hepatic
retinoid levels are elevated [34]. Noteworthy, caution in replacing
vitamin A levels is mandatory as continuous alcohol intake stimu-
lates cytochrome P450 with the conversion of retinoids into toxic
metabolites [35].
Vitamin D deﬁciency has already been reported in ALD, espe-
cially in the presence of established cirrhosis [36]. In a recent
European study on 324 ALD patients, low 25(OH) vitamin D levels
were associated with increased liver damage and mortality, sug-
gesting that vitamin D might be both a biomarker of severity and
a potential therapeutic target in ALD [37]. Notably, a recent Dan-
ish study suggested that a single oral mega-dose (300,000 IU) of
cholecalciferol was  more effective than ergocalciferol in the treat-
ment of vitamin D deﬁciency [38], although these results need to
be reproduced in larger cohorts of ALD patients.
Vitamin E exerts deﬁnite antioxidant effects. However, whilst
several studies have suggested a link between vitamin E deﬁciency
and progression from NAFLD to non-alcoholic steato-hepatitis
(NASH) [39], comparable data in ALD are still scanty.
Vitamin K is a known co-factor for the carboxylation of multi-
ple proteins, including blood coagulation factors and its deﬁciency,
common in advanced liver disease, is usually responsible for bleed-
ing. Despite the lack of speciﬁc studies addressing the vitamin
K status in ALD patients, those with impaired prothrombin time
8 d Liver Disease 47 (2015) 819–825
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Table 4
Summary of general nutrition guidelines for patients with cirrhosis, released by the
European Society for Clinical Nutrition and Metabolism.
Intervention
Overall provision 30–35 kcal/kg dry body weight
Calories distribution (%):
–  Carbohydrates 50–60
– Proteins 25–30 (1–1.5 g/kg body weight)
– Fats 15–20
Avoidance of unnecessary dietary restriction
A  low-sodium diet (<2 g/day) should be recommended only if ascites or
oedema is present
Frequent (4–6) small meals including night-time snacks: to be encouraged
Screen for deﬁciency of serum zinc, calcium and vitamins A, D, E and K and
supplement as needed
Protein restriction for acute hepatic encephalopathy22 R.E. Rossi et al. / Digestive an
nd/or international normalized ratio (INR) should receive vitamin
 supplementation [20].
Summary:  Supplementation with fat-soluble vitamins is not
outinely recommended for ALD patients, except for vitamin D deﬁ-
iency, which should be corrected in all patients with advanced CLD
36].
Grade of recommendation: B.
.3.4. Other nutritional deﬁciencies
A deﬁcit of other micronutrients including ascorbic acid, mag-
esium and zinc, has also been observed in ALD patients, but the
eed for their supplementation remains a matter of debate.
Although full-blown vitamin C deﬁciency is currently uncom-
on  in Western countries, sporadic cases of scurvy have been
escribed in malnourished patients including alcoholics [40,41].
hat prompts for careful skin examination and ascorbic acid mea-
urements when available in this setting [41].
Zinc or magnesium deﬁciency can provoke dysgeusia or altered
aste sensation, partially explaining the decreased dietary intake
eported in most CLD patients [20]. Zinc deﬁciency, common in
iver disease especially in ALD, may  be partially due to decreased
ntake, increased losses secondary to malabsorption, increased
ietary requirement and, possibly, a diuretic regimen [22,42]. The
omplications of zinc deﬁciency include skin lesions, impaired
ight vision, altered taste and smell, immune dysfunction, hypogo-
adism, encephalopathy, altered protein metabolism and retarded
ound healing [42]. The severity of zinc deﬁciency parallels the
xtent of liver damage as suggested by lower serum zinc levels in
lcoholic cirrhotics vs. non-cirrhotics, both groups showing a sig-
iﬁcant decrease of serum zinc levels when compared to healthy
ontrols [43]. According to some studies, zinc supplementation can
evert the known manifestations of zinc deﬁciency in ALD [44],
ven if the results remain inconclusive. In the series by Zarski
t al.  zinc sulfate was given at a dosage of 600 mg/daily for 10
ays to ALD patients and for 10, 30, and 60 days to alcoholic cir-
hotics; both groups normalized serum zinc levels without adverse
eactions, although some cirrhotics maintained persistently low
evels [45]. Bianchi and colleagues administered a long-term oral
inc supplementation (200 mg  tid for 2–3 months) to cirrhotic
atients, including alcoholics, with beneﬁcial effects on both the
iver metabolic function and nutrition parameters [46]. Since nutri-
ional parameters remained below lower limits of normal, further
tudies are needed on both the interaction between zinc and ALD
nd the long-term outcome of oral zinc supplementation, to deﬁne
he optimal duration and overall dose.
Magnesium deﬁciency affects patient’s appetite, and its levels
ave been shown to be an independent predictor of muscle strength
47]. The mechanisms underlying magnesium deﬁciency are still far
rom being fully understood as its deﬁcit may  be due to cirrhosis or
eavy alcohol intake as well. Additionally, the need for magnesium
upplementation is still controversial [47].
Other minerals, such as selenium, may  decrease with liver dis-
ase but the effects are poorly known in cirrhotic patients [20].
Summary:  Guidelines for assessing micronutrient deﬁciency in
LD patients are scanty and evidence supporting their supplemen-
ation is still inconclusive. Moreover, the potential beneﬁts and the
ossible harmful effects of any dietary supplementation should be
onsidered.
Grade of recommendation: D.
.4. Nutritional therapeutic approaches.4.1. Dietary interventions
Dietary interventions represent a relevant step in the manage-
ent of patients with ALD to reduce the length of hospital stay, toIn case of protein intolerance: vegetable or dairy and branched chain amino
acids
improve the outcome of surgery and transplantation and to reduce
the rate of complications [8].
Nutritional management should ﬁrstly be addressed to cover
basal needs and then to provide additional sources for the hyperme-
tabolic state. Caloric need estimation for ALD patients, based on the
Harris-Benedict equation, may  be inaccurate owing to an underes-
timate of the caloric needs by even 15–18% when compared with
the measurement using indirect calorimetry [8]. General nutri-
tional guidelines for patients with cirrhosis as released by the
ESPEN are listed in Table 4 [48]. Unnecessary dietary restrictions
should be avoided in order to reduce the risk of malnutrition or
micronutrient deﬁciency and a low-sodium diet should be only rec-
ommended in decompensated cirrhosis with ascites and oedema.
Due to the limited reserves and inability of the liver to handle pro-
longed starvation due to reduced gluconeogenesis, patients with
cirrhosis are recommended to assume frequent meals, including
nighttime snacks [49]. In this context, a randomized controlled trial
(RCT) reported an increase of the total body protein stores, with a
sustained gain of 2 kg over a 12-month period, in patients receiv-
ing a nighttime snack when compared with patients receiving an
equicaloric diet but lacking the late evening meal [49]. Addition-
ally, cirrhotic patients fasting for more than 12 hours should receive
intravenous glucose at the rate of endogenous hepatic glucose
production (2–3 mg/kg/d). Protein restriction should be limited to
patients with acute hepatic failure, whilst such restriction is not
required in the medium or long-term management of patients
with liver disease as this limitation may  be responsible for an
increased incidence of complications related to malnutrition [50].
In a recent RCT 30 cirrhotic patients hospitalized for an episode of
encephalopathy received a 14-day low-protein regimen with pro-
gressive increments or a normal protein diet, in addition to the
standard measures to treat hepatic encephalopathy. Overall, the
protein intake of 1.2 g/kg/day prevented muscle catabolism with-
out the concomitant precipitation of hepatic encephalopathy [51].
The ESPEN consensus guidelines recommend that the daily pro-
tein intake in patients with liver disease should possibly be from
1.0 to 1.5 g/kg depending on the degree of hepatic decompensation
[52,53].
Cholesterol intake should be limited, as high cholesterol levels
have been reported to increase the degree of liver ﬁbrosis [54], the
risk of cirrhosis and liver cancer [55] and to suppress the immune
function [56]. The use of statins should be encouraged in cirrhotic
patients with hypercholesterolemia [57].
Branched-chain amino acids (BCAAs) have nutritional and/or
metabolic effects on the liver, muscles, and brain, but their levels
are reduced in cirrhosis. There is evidence that long-term oral
BCAA supplementation (about 0.25 g/kg) both exerts nutritional
beneﬁts and reduces the recurrence rates or symptoms of hepatic
encephalopathy in patients with cirrhosis [59]. However, the
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urrently available studies are often controversial [58]: an initial
CT including 37 cirrhotic patients reported that BCAA supple-
entation was superior to conventional protein supplements in
mproving hepatic encephalopathy [59], whilst two other RCTs
ailed to conﬁrm these ﬁndings [60,61], even if they had a small
ample size (eight and four patients only, respectively) and the
CAAs regimen was short-term (11–12 days). More recently,
wo RCTs including larger cohorts (174 and 646 patients, respec-
ively) focused on the long-term use of BCAAs (1–2 years) among
atients with alcoholic cirrhosis; both studies reported a decreased
orbidity and mortality and an improved quality of life in the
roup receiving BCAAs [62,63]. According to available data, BCAA
upplementation should be recommended in ALD patients with
epatic encephalopathy. BCAA-enriched formulae are available
or patients with hepatic encephalopathy who require enteral
utrition (EN) by a nasogastric tube.
Summary: ALD patients should avoid unnecessary dietary
estrictions. Cirrhotic patients should receive a daily protein intake
f approximately 1.0–1.5 g/kg and should have frequent meals
ncluding night-time snacks. Intravenous glucose should be admin-
stered to cirrhotic patients fasting for more than 12 hours; BCAA
upplementation should be performed in ALD patients with hepatic
ncephalopathy.
Grade of recommendation: B.
.4.2. Enteral nutrition (EN)
In ALD patients unable to meet their caloric requirements
hrough normal feeding, supplementary EN ensures the adequate
nergy and protein intake without the risk of complications includ-
ng hepatic encephalopathy [12].
EN is largely preferred over parenteral nutrition (PN) due to the
ower incidence of serious complications and far lower costs. More-
ver, the presence of luminal nutrients represents an important
rophic factor for intestinal mucosa, which may  prevent bacterial
ranslocation and maintain gastrointestinal functions.
Whole protein formulae are generally recommended and more
oncentrated high-energy formulae are preferable in patients with
scites to avoid ﬂuid unbalance. BCAA-enriched formulae should be
dministered to patients with encephalopathy [12]. The oral route
s preferable; however, in the case of inadequate oral intake due to
he disease severity, tube feeding is recommended, even in patients
ith oesophageal varices who can safely undergo the procedure
ithout any risk of variceal haemorrhage [64]. On the other hand,
ercutaneous endoscopic gastrostomy (PEG) should be avoided in
he presence of ascites and coagulopathy [65].
Five RCTs have shown an improvement both in nutritional sta-
us and liver function with EN in patients with AH [17,66–69], but
ata on the long-term survival are often inconclusive as limited to
 small samples or derived from a short-term follow-up. Notewor-
hy, Cabré et al. enrolled 71 patients with severe AH randomized
o receive 40 mg/day prednisolone (n = 36) or enteral tube feed-
ng (2000 kcal/day) for 28 days (n = 35) and followed for one year
r until death. Eventually, EN was comparable to steroids in the
hort-term, although death occurred earlier with EN. Steroid ther-
py however was associated with a higher mortality rate in the
mmediate weeks after treatment, mainly because of infections
17]. Similar results have been reported in a series including 273
ale patients and comparing oxandrolone plus enteral feeding
s. placebo in severe AH. Combined treatment obtained a lower
ortality at six months in the subset of patients with moderate
alnutrition [68], supporting the preference for early EN to be
aintained for a sufﬁcient period.
Four RCTs comparing EN with a standard diet in alcoholic cir-
hotics have shown the improvement in nutritional parameters
nd liver function with EN; however, the data on survival was
onﬂicting, due to the heterogeneity in both the sample size and Disease 47 (2015) 819–825 823
the inclusion/exclusion criteria [70–73]. In particular, in the trials
by Cabré et al. and Kearns et al. [71,73] the results are difﬁcult to
interpret due to the large number of patients with AH, which is
known to beneﬁt from EN [17] and the low number of patients
included in the ﬁrst series [71].
In a recent multicentre prospective RCT including 99 alcoholic
cirrhotics with jaundice but without AH, patients were random-
ized to receive either conventional symptomatic treatment alone
(n = 55) or in association with EN with a supply of 35 kcal/kg/day
for four weeks, followed by an oral nutritional support alone last-
ing two months (n = 44) [74]. Disappointingly, EN failed to improve
survival and hepatic or nutritional parameters, even if results could
have been partially inﬂuenced by the inclusion of Child–Pugh C
cirrhotic patients with ascites, suggesting the use of EN in earlier
stages of ALD.
Summary:  EN is preferable over PN whenever feasible and is
associated with improvement in nutritional status and liver func-
tion in ALD patients, even if data on long-term survival are often
inconclusive.
Grade of recommendation: A.
3.4.3. Parenteral nutrition (PN)
EN has been reported to be as effective as PN, though with lower
costs and fewer side effects, therefore the current indication for PN
support is restricted to a small group of ALD patients for whom
enteral feeding has failed or is contraindicated, or when patients
need to stay fasting for 72 h or more [48].
PN should be started early in ALD patients with moderate or
severe malnutrition, who  cannot be sufﬁciently fed either orally or
enterally [48]. PN should be administered via a central catheter,
carefully considering the increased risk of several complications
such as sepsis, venous thrombosis, pneumothorax, and lymphatic
duct damage. In patients with long-lasting and severe malnutri-
tion, an extremely cautious introduction of PN and careful patient
monitoring for the risk of re-feeding syndrome are of paramount
relevance.
In 1980 a RCT by Nasrallah et al. [75] reported an improved sur-
vival in 18 AH patients receiving parenteral supplementation of
70–85 g of amino acids in addition to a standard diet (3000 kcal/day
and protein 100 g/day) when compared to 17 similar cases on
standard diet alone. Unfortunately, six further studies failed to
conﬁrm the above promising results [76–81], probably due to the
different inclusion criteria, as the study by Nasrallah et al. included
mild to moderate AH. Notably, an improvement in nutritional status
and nitrogen balance was reported in all these studies. In partic-
ular, in a RCT from Simon et al., 12 patients with moderate and
22 with severe AH were randomized for a four-week regimen of
peripheral PN or standard therapy; comparable results were found
in moderate AH, but with a more rapid improvement in liver tests,
particularly bilirubin levels in severe alcoholic hepatitis, without
deleterious effects on encephalopathy or ascites [79].
The role of PN in alcoholic cirrhotics has been reported in
only one series in which 40 in-patients with total serum biliru-
bin greater than or equal to 5 mg/dl were randomized to receive
an oral diet containing 40 kcal per kg per day alone or in combina-
tion with parenteral supplementation (40 kcal/kg/day and 200 mg
nitrogen/kg/day using a central catheter). Despite an improvement
in bilirubin and nutritional status in the PN subset, overall survival
did not improve and was  comparable in both groups (5%) [77].
Summary: PN should be limited to a small group of ALD patients
for whom enteral feeding has failed or is contraindicated or when
patients need to stay fasting for at least 72 hours. PN showed
promising results in terms of improvement in the nutritional status
of ALD patients, however data on survival are inconclusive.
Grade of recommendation: A.
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Table 5
Summary of current evidence about nutritional supplementation in alcoholic liver
disease patients.
Key points
Alcoholic liver disease patients are at high risk for malnutrition and when
malnourished can develop complications negatively affecting both the
clinical outcome and healthcare costs.
The European Society for Clinical Nutrition and Metabolism recommends the
bedside nutritional assessment using Subjective Global Assessment and
anthropometric measurements.
Further studies are needed to clearly deﬁne the role of nutrient
supplementation in alcoholic liver disease patients.
Alcoholic liver disease patients should be screened at baseline for
micronutrient depletion and properly supplemented when necessary.
Folate, vitamin B1 and B12 deﬁciency should be promptly treated to avoid
complications. Inconclusive results are currently available regarding the
therapeutic effect of folate’s ﬁnal metabolite.
Vitamin D deﬁciency should be treated and corrected.
The actual need for supplementation of micronutrients including ascorbic acid,
zinc, selenium and magnesium in alcoholic liver disease patients remains to
be  determined.
Unnecessary dietary restrictions should be avoided and appropriate dietary
intake should be given according to European Society for Clinical Nutrition
and Metabolism recommendations.
Both enteral (ﬁrst choice whenever possible), and parenteral nutrition seem to
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[improve the nutritional parameters and liver function. However, their effect
on survival remains to be proven.
. Conclusion
Patients with ALD are at high risk for malnutrition, which in turn
arries a high risk of developing complications, negatively affecting
linical outcome and increasing healthcare costs. Thus, physicians
hould detect, diagnose and treat nutritional deﬁciencies early
n this subset of patients. The baseline evaluation of a patient’s
utritional status by SGA and anthropometric measurements is rec-
mmended by the ESPEN. Nutritional support for malnourished
LD patients is aimed at improving the outcome of hospitaliza-
ion, surgical procedures, and transplantation and at reducing the
ength of hospital stay and the rate of complications. Neverthe-
ess, there is still no approved therapy for this common and often
evastating disease. Both EN, the ﬁrst choice whenever possible,
nd PN seem to improve nutritional parameters and liver function
n ALD patients, but fail in increasing overall survival. Micronu-
rient depletion is common in ALD patients and each deﬁciency
roduces speciﬁc sequelae. According to the ESPEN guidelines, all
irrhotic patients should be screened at baseline for deﬁciencies
f micronutrients and then properly supplemented. Summary of
urrent evidence on nutritional supplementation in ALD patients is
eported in Table 5.
A complete nutritional assessment, evaluation for EN, PN and
icronutrient supplementation supports the need for a multi-
isciplinary management of ALD patients.
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